Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arctic Bioscience AS ( (DE:9TD) ) has issued an update.
Arctic Bioscience will release its operational update for the first quarter of 2026 on 30 April, with the report scheduled for publication early in the morning. Later that day, management will present the update in a bilingual webcast, followed by a question-and-answer session for investors and other participants.
The webcast will be conducted in Norwegian and English and made accessible via an online link provided by the company. The announcement underscores Arctic Bioscience’s effort to maintain transparent communication with the market in line with securities disclosure requirements, giving stakeholders a chance to engage directly with the leadership team.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements derived from bioactive marine raw materials. The company is advancing HRO350, an oral drug candidate for mild-to-moderate psoriasis, and markets its marine-based dietary supplements globally as bulk ingredients and finished products under the ROMEGA brand.
Average Trading Volume: 16,349
Current Market Cap: NOK93M
For an in-depth examination of 9TD stock, go to TipRanks’ Overview page.